VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
04 juin 2019 08h00 HE
|
VBI Vaccines, Inc.
Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...
National Brain Tumor Society Cites Ten Reasons for Brain Tumor Community Excitement in 2017
10 janv. 2017 17h35 HE
|
National Brain Tumor Society
BOSTON, MA--(Marketwired - January 10, 2017) - National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community, enters 2017 with greater enthusiasm about its mission...
Stellar Biotechnologies to Present at ImVacS 2012 Summit on August 13-16, 2012
25 juin 2012 10h55 HE
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Jun 25, 2012) - Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) is pleased to report that an abstract prepared...